Skip to content

Study · Observational study · n = 214 · 2024

6 results

Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.

Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A

Diabetes, obesity & metabolism13 Mar 2024Cited by 26 (Europe PMC)

PMID38477183 (opens in a new tab)DOI10.1111/dom.15554 (opens in a new tab)PepBankPUB-38477183
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the proportion of low, intermediate and high doses was similar with oral and injectable semaglutide.

    In plain wordsIn adults with type 2 diabetes, oral and injectable semaglutide were used at similar dose levels.

    Peptide
    Semaglutide
    Outcome
    No significant changeDose exposure, oral versus injectable
    Study

    n = 214

    Comparator
    Oral semaglutide versus injectable semaglutide
    Outcome group
    Patterns of use · Metabolic and weight
    Studied dose
    Dose not stated · oral or injectable · up to 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The proportion of low, intermediate and high doses were similar with the oral and the injectable formulation.
    2 context sentences
    Summary · context
    New users of oral or injectable semaglutide were selected from a cohort of 14 079 initiators of glucagon-like peptide-1 receptor agonists.
    Summary · context
    We analysed two matched groups of 107 participants each, who comprised on average 63.6% men, aged 64 years, with diabetes duration of approximately 10 years, body mass index of 29 kg/m2 and HbA1c level of 7.7-7.8% (61-62 mmol/mol).
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, HbA1c change was similar between oral and injectable semaglutide.

    In plain wordsIn adults with type 2 diabetes, oral and injectable semaglutide lowered HbA1c by a similar amount.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c change at 18 months, oral versus injectable
    Study

    n = 214

    Comparator
    Oral semaglutide versus injectable semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral or injectable · up to 18 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.9%
    both groups, 18 months

    Source sentences

    Summary
    The change in HbA1c was similar between groups (-0.9% / -10 mmol/mol at 18 months)
    2 context sentences
    Summary · context
    New users of oral or injectable semaglutide were selected from a cohort of 14 079 initiators of glucagon-like peptide-1 receptor agonists.
    Summary · context
    We analysed two matched groups of 107 participants each, who comprised on average 63.6% men, aged 64 years, with diabetes duration of approximately 10 years, body mass index of 29 kg/m2 and HbA1c level of 7.7-7.8% (61-62 mmol/mol).
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the proportion reaching HbA1c below 6.5% was similar between oral and injectable semaglutide.

    In plain wordsIn adults with type 2 diabetes, a similar share of people on oral and injectable semaglutide reached HbA1c below 6.5%.

    Peptide
    Semaglutide
    Outcome
    No significant changeReaching HbA1c below 6.5%, oral versus injectable
    Study

    n = 214

    Comparator
    Oral semaglutide versus injectable semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral or injectable · up to 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The change in HbA1c was similar between groups (-0.9% / -10 mmol/mol at 18 months) as was the proportion of individuals reaching HbA1c <6.5% (48 mmol/mol).
    2 context sentences
    Summary · context
    New users of oral or injectable semaglutide were selected from a cohort of 14 079 initiators of glucagon-like peptide-1 receptor agonists.
    Summary · context
    We analysed two matched groups of 107 participants each, who comprised on average 63.6% men, aged 64 years, with diabetes duration of approximately 10 years, body mass index of 29 kg/m2 and HbA1c level of 7.7-7.8% (61-62 mmol/mol).
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, average body weight change was similar with injectable (-3.7 kg) and oral (-3.3 kg) semaglutide at 18 months.

    In plain wordsIn adults with type 2 diabetes, oral and injectable semaglutide led to a similar weight change at 18 months.

    Peptide
    Semaglutide
    Outcome
    No significant changeBody weight change at 18 months, oral versus injectable
    Study

    n = 214

    Comparator
    Oral semaglutide versus injectable semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral or injectable · up to 18 monthsAs given in this study (human).

    Measurements

    Body weight change
    −3.7 kg
    injectable
    Body weight change
    −3.3 kg
    oral

    Source sentences

    Summary
    The average change in body weight was similar in the two groups (-3.7 kg with injectable and -3.3 kg with oral at 18 months)
    2 context sentences
    Summary · context
    New users of oral or injectable semaglutide were selected from a cohort of 14 079 initiators of glucagon-like peptide-1 receptor agonists.
    Summary · context
    We analysed two matched groups of 107 participants each, who comprised on average 63.6% men, aged 64 years, with diabetes duration of approximately 10 years, body mass index of 29 kg/m2 and HbA1c level of 7.7-7.8% (61-62 mmol/mol).
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, more new users of injectable than oral semaglutide lost 5% or more of body weight.

    In plain wordsIn adults with type 2 diabetes, more people on injectable semaglutide than oral semaglutide lost at least 5% of body weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseLosing 5% or more body weight, oral versus injectable
    Study

    n = 214

    Comparator
    Oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral or injectable · up to 18 monthsAs given in this study (human).

    Source sentences

    Summary
    but more new users of injectable semaglutide lost ≥5% body weight.
    2 context sentences
    Summary · context
    New users of oral or injectable semaglutide were selected from a cohort of 14 079 initiators of glucagon-like peptide-1 receptor agonists.
    Summary · context
    We analysed two matched groups of 107 participants each, who comprised on average 63.6% men, aged 64 years, with diabetes duration of approximately 10 years, body mass index of 29 kg/m2 and HbA1c level of 7.7-7.8% (61-62 mmol/mol).
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, persistence on drug was longer with injectable than with oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, people stayed on injectable semaglutide longer than on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreasePersistence on drug, oral versus injectable
    Study

    n = 214

    Comparator
    Oral semaglutide
    Outcome group
    Patterns of use · Metabolic and weight
    Studied dose
    Dose not stated · oral or injectable · up to 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Persistence on drug was longer with injectable than with oral semaglutide.
    2 context sentences
    Summary · context
    New users of oral or injectable semaglutide were selected from a cohort of 14 079 initiators of glucagon-like peptide-1 receptor agonists.
    Summary · context
    We analysed two matched groups of 107 participants each, who comprised on average 63.6% men, aged 64 years, with diabetes duration of approximately 10 years, body mass index of 29 kg/m2 and HbA1c level of 7.7-7.8% (61-62 mmol/mol).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.